<scp>Interleukin‐17RA</scp> blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum

Abstract

IL-17RA inhibition by brodalumab decreases several pathogenic inflammatory axes in HS. Perilesional skin provides a valid and robust assessment of treatment response. Expression of LCN2 in skin or IL-17A in serum may be used as biomarkers to stratify patients that may have a superior molecular response to brodalumab.